![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1624233
´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø : ¼¼°è ¹× Áö¿ª Á¡À¯À², µ¿Çâ, ¼ºÀå ±âȸ ºÐ¼® ¸®Æ÷Æ® - À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°Mononucleosis Diagnostic Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, End User, and Geography |
The Insight PartnersÀÇ ÃֽŠÁ¶»ç ¸®Æ÷Æ® '´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀå ¿¹Ãø(-2031³â) : ¼¼°è ºÐ¼® - À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°'¿¡ µû¸£¸é ½ÃÀåÀº 2023³â 1¾ï 5,144¸¸ ´Þ·¯¿¡¼ ¼ºÀåÇϸç, 2031³â¿¡´Â 2¾ï 2,215¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2023-2031³â¿¡ CAGR 4.9%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. û¼Ò³â Àα¸ÀÇ ³ôÀº À§Çèµµ, ´ÜÇÙ±¸Áõ¿¡ ´ëÇÑ °Ç° Àνİú Áö½Ä Áõ°¡´Â ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀå ±Ô¸ð È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ±âÁ¸ Áø´Ü °Ë»çÀÇ ³·Àº Á¤È®µµ´Â ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ´ÜÇÙ±¸Áõ Áø´ÜÀÇ ºÐÀÚÁø´ÜÇÐÀÇ ¹ßÀüÀº ÇâÈÄ ¼ö³â°£ »õ·Î¿î ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀå µ¿ÇâÀ» °¡Á®¿Ã °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¸ÅÃâ¾× ±âÁØÀ¸·Î´Â ºÏ¹Ì°¡ 2023³â ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù. ¿¹Ãø ±â°£ Áß¿¡µµ ¼¼°è ½ÃÀåÀ» µ¶Á¡ÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¹Ì±¹Àº ¼¼°è ÃÖ´ë ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀåÀ̸ç, ¿¹Ãø ±â°£ Áß¿¡µµ ½ÃÀåÀ» Áö¹èÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹Ì±¹ ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀº ±â¼ú ¹ßÀü, ÀÎ½Ä °³¼±, È¿°úÀûÀÎ Áúº´ °ü¸® Àü·«¿¡ ´ëÇÑ ²÷ÀÓ¾ø´Â ¼ö¿ä¿¡ ±âÀÎÇÕ´Ï´Ù. ¹Ì±¹ ±¹¸³º¸°Ç¿ø¿¡ µû¸£¸é ¹Ì±¹¿¡¼´Â ¸Å³â 125,000°ÇÀÇ Àü¿°¼º ´ÜÇÙ±¸Áõ ȯÀÚ°¡ ¹ß»ýÇÕ´Ï´Ù. ÀÌ·¯ÇÑ È¯ÀÚ ¼ö·Î ÀÎÇØ ¿¦½ºÅ¸ÀÎ-¹Ù ¹ÙÀÌ·¯½º(EBV)·Î ÀÎÇÑ ´ÜÇÙ±¸Áõ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼ ½Å¼ÓÇϰí Á¤È®ÇÑ Áø´Ü Å×½ºÆ® ŰƮ, ¼Ò¸ðǰ ¹× ¼ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¹Ì±¹³» ÀÇ·á ¼ºñ½º ÇÁ·Î¹ÙÀÌ´õµéÀÌ »ç¿ëÇÏ´Â ´Ù¾çÇÑ °Ë»ç ¹æ¹ý¿¡´Â Ç×ü °ËÃâ¿¡ ±â¹ÝÇÑ Ç÷ûÇÐÀû °Ë»ç, ¹ÙÀÌ·¯½º DNA ½Äº°¿¡ ÃÊÁ¡À» ¸ÂÃá ºÐÀÚ °Ë»ç µîÀÌ ÀÖ½À´Ï´Ù. ¹Ì±¹ ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀå °æÀï ±¸µµ´Â Abbott Laboratories, Roche Diagnostics, Siemens Healthineers µîÀÌ ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÀÌµé ±â¾÷Àº Á¦Ç° ¶óÀξ÷À» °ÈÇÏ°í ½ÃÀå¿¡¼ÀÇ ÀÔÁö¸¦ È®´ëÇϱâ À§ÇØ ±â¼ú Çõ½Å°ú Á¦ÈÞ¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù.
´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀå ºÐ¼®
POC °Ë»çÀÇ °³¹ßÀº ÇâÈÄ ½ÃÀå ±âȸ¸¦ °¡Á®¿Ã °ÍÀÔ´Ï´Ù.
ÇöÀåÁø´Ü(POC) °Ë»ç´Â ȯÀÚÀÇ Ä¡·á ÇöÀå ¶Ç´Â ±× ±Ùó¿¡¼ ½Å¼ÓÇÑ Áø´ÜÀ» °¡´ÉÇÏ°Ô ÇÏ¿© ÀÇ·áÁøÀÌ Áï°¢ÀûÀÎ ÀÓ»óÀû ÆÇ´ÜÀ» ³»¸®°í ȯÀÚÀÇ °á°ú¸¦ °³¼±ÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. ±âÁ¸ ÀÓ»ó °Ë»ç´Â °á°ú°¡ ³ª¿À±â±îÁö ¸î ½Ã°£¿¡¼ ¸çÄ¥ÀÌ °É¸®´Â °æ¿ì°¡ ¸¹¾Æ Ä¡·á°¡ Áö¿¬µÇ°Å³ª Áõ»óÀÌ ¾Ç鵃 ¼ö ÀÖ½À´Ï´Ù. ¹Ý¸é, POC °Ë»ç´Â ¸î ºÐ ¾È¿¡ °á°ú¸¦ ¾òÀ» ¼ö ÀÖÀ¸¸ç, Àû½Ã¿¡ °³ÀÔÇÒ ¼ö ÀÖ½À´Ï´Ù. Á¶±â Áø´ÜÀº ÇÕº´ÁõÀ» ÁÙÀ̰í ȯÀÚÀÇ Æí¾ÈÇÔÀ» Áõ°¡½Ãų ¼ö ÀÖÀ¸¹Ç·Î ´ÜÇÙ±¸Áõ°ú °°Àº Áúº´¿¡ ÀÖÀ¸¸ç, ½Å¼ÓÇÑ °á°ú´Â ƯÈ÷ Áß¿äÇϸç, POC °Ë»ç´Â ¿Ü·¡ Áø·á¼Ò, ÀÀ±Þ½Ç, ÀçÅà ġ·á µî ´Ù¾çÇÑ ÀÇ·á ȯ°æ¿¡¼ ½ÃÇàÇÒ ¼ö ÀÖ½À´Ï´Ù. °Ë»ç ÀÎÇÁ¶ó°¡ Á¦ÇÑÀûÀÎ Áö¿ªÀ̳ª ÀÇ·á ÀÚ¿øÀÌ ºÎÁ·ÇÑ Áö¹æ¿¡¼´Â Á¢±Ù¼ºÀÌ Æ¯È÷ À¯¿ëÇϸç, POC °Ë»çÀÇ ÇüÅ·ΠÁø´Ü ´É·ÂÀ» ȯÀÚ¿¡°Ô ´õ °¡±îÀÌ °¡Á®¿Í ´õ ¸¹Àº »ç¶÷µéÀÌ Àû½Ã¿¡ Áø´Ü°ú ÀûÀýÇÑ Ä¡·á¸¦ ¹ÞÀ» ¼ö ÀÖÀ¸¸ç, ÀÇ·á ¼ºñ½ºÀÇ ¹üÀ§¸¦ ³ÐÈú ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ À¯ÇüÀÇ Å×½ºÆ®´Â ȯÀÚ°¡ ½Å¼ÓÇÏ°Ô °á°ú¸¦ ¹Þ°í ´ÙÀ½ ´Ü°è¿¡ ´ëÇØ ÀÇ·á ¼ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿Í ³íÀÇÇÒ ¼ö ÀÖÀ¸¹Ç·Î ´õ ¸¹Àº Âü¿©¸¦ ÃËÁøÇÕ´Ï´Ù.
POC °Ë»ç´Â ´ë±Ô¸ð °Ë»ç ÀÎÇÁ¶ó¸¦ ÇÊ¿ä·Î ÇÏÁö ¾Ê±â ¶§¹®¿¡ ±âÁ¸ °Ë»ç½Ç °Ë»ç¿¡ ºñÇØ ºñ¿ë È¿À²ÀûÀ̸ç, °á°úÀûÀ¸·Î Àüü ÀÇ·á ½Ã½ºÅÛ ºñ¿ëÀ» ³·Ãâ ¼ö ÀÖ½À´Ï´Ù. ´ÜÇÙ±¸Áõ °Ë»çÀÇ Àú·ÅÇÑ °¡°ÝÀº ƯÈ÷ ÀÇ·á ¼ºñ½º¸¦ ÃæºÐÈ÷ ¹ÞÁö ¸øÇϴ ȯÀÚÃþ µî º¸´Ù ±¤¹üÀ§ÇÑ È¯ÀÚ Á¢±Ù¼ºÀ» ´õ¿í ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÃÖ±Ù ¹ÙÀÌ¿À¼¾¼ ¹× ¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º ±â¼úÀÇ ¹ßÀüÀ¸·Î ¹Î°¨µµ¿Í ƯÀ̵µ°¡ Çâ»óµÈ º¸´Ù Á¤±³ÇÑ ÇöÀåÁø´Ü(POC) °Ë»çÀÇ °³¹ßÀÌ °¡¼Óȵǰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ´ÜÇÙ±¸Áõ °ËÃâ¿¡ ÀÖÀ¸¸ç, POC °Ë»çÀÇ ½Å·Ú¼ºÀ» º¸ÀåÇϰí ÀÖÀ¸¸ç, POC °Ë»ç ŰƮ¸¦ Á¦°øÇÏ´Â ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀå ±â¾÷À¸·Î´Â SEKISUI Diagnostics(OSOM Mono Test), Abbott(Clearview Mono), Cardinal Health(Cardinal Health) µîÀÌ ÀÖ½À´Ï´Ù. Cardinal Health(Cardinal Health MONO(Mononucleosis) II Rapid Test) µîÀÌ ÀÖ½À´Ï´Ù. ÀÌó·³ POC °Ë»çÀÇ °³¹ßÀº ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀåÀÇ ±â¾÷¿¡°Ô ½ÇÁúÀûÀÎ ¼ºÀå ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù.
´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀå º¸°í¼ ¼¼ºÐÈ ºÐ¼®
´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀåÀÇ ºÐ¼®¿¡ ±â¿©ÇÑ ÁÖ¿ä ºÎ¹®Àº À¯Çü ¹× ÃÖÁ¾»ç¿ëÀÚÀÔ´Ï´Ù.
À¯Çüº°·Î ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀåÀº ¾Û½ºÅ¸ÀÎ ¹Ù ¹ÙÀÌ·¯½º Ç×ü °Ë»ç, ÀüÇ÷±¸ °è»ê °Ë»ç, ¸ð³ë½ºÆÌ °Ë»ç·Î ±¸ºÐµÇ¸ç, 2023³â ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀåÀº ¸ð³ë½ºÆÌ °Ë»ç ºÎ¹®ÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÃÖÁ¾»ç¿ëÀÚº°·Î ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀåÀº º´¿ø, ¿¬±¸¼Ò, ±âŸ·Î ºÐ·ùµÇ¸ç, 2023³â¿¡´Â º´¿ø ºÎ¹®ÀÌ ½ÃÀåÀ» Àå¾ÇÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀå °æÀï ±¸µµ ¹× ÁÖ¿ä ¹ßÀü »óȲ
Abbott Laboratories, Arlington Scientific Inc, Bio-Rad Laboratories Inc, Cardinal Health Inc, Meridian Bioscience Inc, Sekisui Diagnostics LLC, Thermo Fisher Scientific Inc, QuidelOrtho Corp, F. Hoffmann-La Roche Ltd, QIAGEN NV, Hologic Inc, bioMerieux SA, DiaSorin SpA, Immunostics Inc, Launch Diagnostics Ltd, Biorex Diagnostics, ZEUS ScientificÀº ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀå¿¡¼ »ç¾÷À» µµÀÔÇϰí ÀÖ´Â ÁÖ¿ä ±â¾÷ÀÔ´Ï´Ù.
À¯¿£¾Æµ¿±â±Ý(UNICEF), ±¹¸³ÀÇÇеµ¼°ü, Áúº´ÅëÁ¦¿¹¹æ¼¾ÅÍ(CDC), ±¹¸³º¸°Ç¿ø, ij³ª´Ù Åë°èû, ¿¬¹æÅë°èû(Destatis) µîÀº ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀå º¸°í¼ ÀÛ¼º½Ã Âü°íÇÑ 1Â÷ ¹× 2Â÷ Á¤º¸ÀÔ´Ï´Ù.
According to our new research study on "Mononucleosis Diagnostic Market Forecast to 2031 -Global Analysis - by Type, End User, and Geography," the market is anticipated to grow from US$ 151.44 million in 2023 and is projected to reach US$ 222.15 million by 2031; it is expected to register a CAGR of 4.9% during 2023-2031. High risk among the adolescent population, and the rising health awareness and knowledge about mononucleosis are contributing to the growing mononucleosis diagnostic market size. However, the low accuracy of existing diagnostic tests hampers the mononucleosis diagnostic market growth. Further, advancements in molecular diagnostics in mononucleosis diagnostic are expected to bring in new mononucleosis diagnostic market trends in the coming years.
In terms of revenue, North America dominated the mononucleosis diagnostic market in 2023. It is estimated to dominate the global market during the forecast period. The US is the largest market for mononucleosis diagnostics in the world, and it is estimated to dominate the market during the forecast period as well. The mononucleosis diagnostic market growth in the US is attributed to technological advancements, increased awareness, and a constant need for effective disease management strategies. According to the National Institutes of Health, the US records ~125,000 cases of infectious mononucleosis every year. Owing to such a high number, the awareness of the mononucleosis caused by the Epstein-Barr virus (EBV) is also on the rise in the country, which bolsters the demand for rapid and accurate diagnostic test kits, consumables, and services. Various testing methods adopted by healthcare providers in the country include serological tests based on antibody detection and molecular tests focused on viral DNA identification. The competitive landscape of the mononucleosis diagnostics market in the US is dominated by companies such as Abbott Laboratories, Roche Diagnostics, and Siemens Healthineers. These companies invest in innovation and collaborations to enhance their product offerings and expand their market presence.
Mononucleosis Diagnostic Market Analysis
Development of Point-of-Care Testing to Provide Market Opportunities in Future
POC testing allows for rapid diagnosis at or near the site of patient care, enabling healthcare providers to make immediate clinical decisions and improve patient outcomes. Traditional laboratory tests often require hours or days to generate results, which can delay treatment and worsen symptoms. In contrast, POC tests can deliver results within minutes, facilitating timely intervention. The rapid turnaround is especially crucial for conditions such as mononucleosis, as early diagnosis can reduce complications and enhance patient comfort. POC testing can be implemented in various healthcare settings, including outpatient clinics, emergency departments, and home care settings. The accessibility is particularly beneficial in areas with limited laboratory infrastructure or in rural regions with insufficient healthcare resources. Bringing diagnostic capabilities closer to patients in the form of POC testing ensures that more individuals receive timely diagnoses and appropriate care, thereby broadening the reach of healthcare services. Moreover, this type of testing promotes greater engagement, as patients can receive their results quickly and discuss the next steps with their healthcare providers.
POC testing can be more cost-effective compared to traditional laboratory testing as they don't need extensive laboratory infrastructure, in turn lowering the overall costs for healthcare systems. The affordability of mononucleosis testing further drives its accessibility to a broader range of patients, especially in underserved populations. Recent advancements in biosensors and microfluidic technologies are driving the development of more sophisticated POC tests with improved sensitivity and specificity. These innovations ensure the reliability of POC tests in detecting mononucleosis. Mononucleosis diagnostic market players offering POC test kits include SEKISUI Diagnostics (OSOM Mono Test), Abbott (Clearview Mono), and Cardinal Health [Cardinal Health MONO (Mononucleosis) II Rapid Test]. Thus, the development of POC testing generates substantial growth opportunities for the mononucleosis diagnostics market players.
Mononucleosis Diagnostic Market Report Segmentation Analysis
Key segments that contributed to the derivation of the mononucleosis diagnostic market analysis are type and end user.
Based on type, the mononucleosis diagnostic market is segmented into Epstein Barr Virus antibody test, complete blood count test, and monospot test. The monospot test segment held the largest mononucleosis diagnostic market share of the market in 2023.
In terms of end user, the mononucleosis diagnostic market is categorized into hospitals, laboratories, and others. The hospitals segment dominated the market in 2023.
Mononucleosis Diagnostic Market: Competitive Landscape and Key Developments
Abbott Laboratories, Arlington Scientific Inc, Bio-Rad Laboratories Inc, Cardinal Health Inc, Meridian Bioscience Inc, Sekisui Diagnostics LLC, Thermo Fisher Scientific Inc, QuidelOrtho Corp, F. Hoffmann-La Roche Ltd, QIAGEN NV, Hologic Inc, bioMerieux SA, DiaSorin SpA, Immunostics Inc., Launch Diagnostics Ltd, Biorex Diagnostics, and ZEUS Scientific are among the key companies operating in the mononucleosis diagnostic market.
The United Nations Children's Fund (UNICEF), National Library of Medicine, Centers for Disease Control and Prevention (CDC), National Institutes of Health, Statistics Canada, Federal Statistical Office (Destatis) are among the primary and secondary sources referred to while preparing the mononucleosis diagnostic market report.